Form 4: Rhythm Pharmaceuticals Executive Yann Mazabraud Sells Shares Under 10b5-1 Trading Plan

Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, sold shares of common stock on April 8, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, sold shares of the company's common stock on April 8, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 13, 2024.
• A total of 8,438 shares were sold at a weighted average price of $60.3739, with individual prices ranging from $60.00 to $60.91.
• An additional 9,312 shares were sold at a weighted average price of $61.5402, with individual prices ranging from $61.04 to $62.00.
• Following the reported transactions, Mazabraud directly owns 22,620 shares of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock sales under a pre-arranged trading plan. There's no indication of positive or negative implications for the company's performance.

Industry Context

Insider selling can be interpreted in various ways by the market. It's important to consider the context of the 10b5-1 plan, which allows insiders to sell shares at predetermined times to avoid accusations of trading on non-public information. The impact on Rhythm Pharmaceuticals' stock price will depend on overall market conditions and investor sentiment towards the company.

Stakeholder Impact

• Shareholders may react to the insider selling, although the existence of a 10b5-1 plan mitigates concerns about opportunistic trading.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Yann Mazabraud, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Executive, EVP, Head of International